ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 833

A Small Proportion of Patients with Systemic Sclerosis with Suspected Pulmonary Hypertension Meet the Published Inclusion/Exclusion Criteria for Two Systemic Sclerosis Associated Pulmonary Arterial Hypertension Screening Algorithms– Results from a Single Center Cohort

Amber Young1, Victor Moles2, Vivek Nagaraja3, Scott H. Visovatti4, Vallerie McLaughlin4 and Dinesh Khanna5, 1Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, 3Department of Medicine [Division of Rheumatology], University of Toledo, Toledo, OH, 4Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, 5University of Michigan, Ann Arbor, MI

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: scleroderma and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Pulmonary arterial hypertension (PAH) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). Active screening detects SSc-PAH earlier and may improve survival. Our objective was to evaluate the predictive accuracy of  2012 Australian Scleroderma Interest Group (ASIG) and 2013 DETECT when applied to all patients with SSc with suspected pulmonary hypertension (PH) versus application to only those patients with SSc with suspected PH who met the published inclusion/exclusion criteria for ASIG and DETECT (Table 1).   

Methods: Subjects with a diagnosis of SSc based on 2013 ACR/EULAR classification criteria with suspected PH based on the 2013 recommendations for screening and detection of connective tissue disease (CTD)-associated PAH undergoing right heart catheterization (RHC) were evaluated (Khanna et al.  Arth Rheum. 2013). Those with non-PH or PAH on RHC had ASIG and DETECT applied. Contingency table analysis was used to evaluate sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV).  

Results: Approximately 281 subjects underwent screening for PH, and out of those 281 subjects, 113 subjects underwent RHC based on 2013 recommendations for CTD-PAH or clinical opinion of the referring physician (Figure 1). The prevalence of PAH was 17% (Figure 1). DETECT and ASIG performed similarly with 100% sensitivity and NPV in subjects who met and who did not meet the inclusion/exclusion criteria for ASIG or DETECT (Table 2). However, only approximately 10% of subjects met the original published inclusion/exclusion criteria. The most common reason for not meeting the inclusion/exclusion criteria was a higher DLco value; during ASIG application, 36 subjects did not have a DLco ˂ 50 % predicted and during DETECT application, 29 subjects did not have a DLco ˂ 60 % predicted.  

Conclusion: In a well-defined SSc- PH cohort, ASIG and DETECT work well as screening tools when applied to a broad population of subjects with SSc. If only the published inclusion/exclusion criteria for ASIG AND DETECT are used, a large proportion of subjects (87 to 88%) with suspected PH would have been missed. 


Disclosure: A. Young, None; V. Moles, None; V. Nagaraja, None; S. H. Visovatti, None; V. McLaughlin, None; D. Khanna, Bristol-Myers Squibb, 2,Pfizer Inc, 2,Roche Pharmaceuticals, 5,Sanofi-Aventis Pharmaceutical, 5,BAYER, 5,CYTORI, 5,EMD Serono, 5,Roche Pharmaceuticals, 2,Actelion Pharmaceuticals US, 5.

To cite this abstract in AMA style:

Young A, Moles V, Nagaraja V, Visovatti SH, McLaughlin V, Khanna D. A Small Proportion of Patients with Systemic Sclerosis with Suspected Pulmonary Hypertension Meet the Published Inclusion/Exclusion Criteria for Two Systemic Sclerosis Associated Pulmonary Arterial Hypertension Screening Algorithms– Results from a Single Center Cohort [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/a-small-proportion-of-patients-with-systemic-sclerosis-with-suspected-pulmonary-hypertension-meet-the-published-inclusionexclusion-criteria-for-two-systemic-sclerosis-associated-pulmonary-a/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-small-proportion-of-patients-with-systemic-sclerosis-with-suspected-pulmonary-hypertension-meet-the-published-inclusionexclusion-criteria-for-two-systemic-sclerosis-associated-pulmonary-a/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology